Biomedical Engineering Reference
In-Depth Information
37.
Biotechnol Annu Rev
. 2007;
13:95-113. Advances in antibody
manufacturing using
mammalian cells. Morrow KJ Jr.
Newport Biotechnology
Consultants, 625 Washington
Avenue, Newport, KY 41071.
In this review, we describe recent advances in
antibody processing technology, including: (1)
development of proprietary cell lines; (2) improved
expression systems optimized by selective
technologies to boost underperformers; (3) improved
protein-free and serum-free culture media; and (4)
attention to glycosylation and other posttranslational
modifications. Advances in computer technology
and sophisticated redesign of bioreactors have been
major contributors to the dramatic improvements in
antibody yields that have been documented in the
last decade. Disposable bioreactor components are
now widespread, resulting in improved yields,
better-quality product, and lower costs for
producers. Downstream innovations include (1)
disposable devices for clarification and purification,
(2) improved resins and ligands, and (3) new designs
of hardware for improved performance. While there
are numerous factors contributing to the increased
yields that have been obtained, the most sustained of
these is the introduction of disposable technologies
on both the upstream and the downstream ends of
the process. With the continuing introduction of
improved computer technology and technological
innovation, there is every reason to believe that the
quality and quantity of antibody products will
continue to improve in the coming years, and supply
will be adequate to meet the forthcoming needs of
the industry.
